PortViewPortView
CHB logo

Global X China Biotech Innovation (CHB) ETF Holdings & Analysis

ETFOther

$6.64-0.38%
1-year price historyRange $6.64 – $10.04
52-week range$6.64
$6.63$9.76

What CHB does

This fund commits at least 80% of its overall assets, alongside any borrowed capital used for investment, to the securities tracked by its benchmark index. This also includes American and Global Depositary Receipts that are derived from those same index securities. The underlying index itself is specifically designed to provide investors with exposure to exchange-listed companies operating directly within China's biotechnology sector. Notably, this fund operates on a non-diversified basis.

Fund profile

Category
Other
AUM
$1.39M
Holdings
2
52-week high
$9.76
52-week low
$6.63

Top holdings

Top 2100%
HoldingWeight
CASH99.98%
OTHER PAYABLE & RECEIVABLES0.02%

Sector allocation

Basic Materials0.84%
Healthcare99.16%

Geographic allocation

Other100.00%

PortView Portfolio Insights

PortView analyzes how CHB fits your actual portfolio — position weight, ETF overlap with your other funds, sector and geographic exposure, concentration, and how this fund contributes to your portfolio risk and return. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze CHB in PortView →

Related securities

Related stocks

Frequently asked questions

What does CHB track?
CHB is the Global X China Biotech Innovation ETF, a Other ETF.
What is the expense ratio of CHB?
Expense ratio data for CHB is shown on the page when available from our data provider.
What are the largest holdings in CHB?
Top holdings include CASH, OTHER PAYABLE & RECEIVABLES.
How can PortView analyze CHB overlap with other ETFs?
PortView computes the holdings overlap between CHB and the other ETFs and stocks you own, plus your combined sector and geographic exposure, so you can see true diversification.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.